Pfizer confirms to acquire Global Blood Therapeutics for $5.4 billion in deal that gives it access to sickle-cell disease treatmentMarket Watch • 08/08/22
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare HematologyBusiness Wire • 08/08/22
Pfizer agrees to buy Global Blood Therapeutics in deal valued at $5.4 billion: WSJMarket Watch • 08/08/22
Pfizer in advanced talks to buy Global Blood Therapeutics for about $5 billionFox Business • 08/05/22
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 BillionInvestors Business Daily • 08/05/22
WSJ: Pfizer considering buying Global Blood Therapeutics for roughly $5 billionMarket Watch • 08/05/22
Medicare Drug Pricing Changes Could Be Coming: Time to Ditch Pharma Stocks?The Motley Fool • 08/03/22
Moderna and Pfizer to start clinical trials for COVID-19 boosters that target BA.5 ‘in the near future'Market Watch • 07/29/22
ViiV Healthcare presents positive five-year data at AIDS 2022, demonstrating the durability of fostemsavir in people living with HIV who are heavily treatment-experiencedBusiness Wire • 07/29/22